Inocras, a San Diego-based bioinformatics company focused on whole genome sequencing analysis and interpretation, has raised $31 million in Series B-3 funding. The round brings total funding to approximately $100 million. Inocras provides whole-genome insights for cancer and rare disease diagnosis through its Vision platform products, which use proprietary AI and bioinformatics to deliver clinically actionable reports. The capital will accelerate U.S. commercial expansion.
Korean Capital Backs U.S. Genomics Push
The timing aligns with growing clinical validation of whole-genome approaches over targeted panels. Inocras has already deployed its technology across more than 100 cancer institutions in Asia and 30 hospitals in South Korea. Strategic investors NDS Corporation and Aimed Bio Inc. participated alongside financial backers including IMM Investment, Korea Investment & Securities, Woori Investment & Securities, and Shinhan Securities. Existing investors DSC Investment, Dunamu & Partners, and InterVest also joined.
Panels Miss Actionable Variants
Targeted panels and exome sequencing capture only 0.01-2% of the genome and miss over 25% of complicated mutations that whole-genome sequencing detects. Inocras reports that its approach yields 10-20% additional diagnoses for rare disease cases compared to panel or exome methods. Its CancerVision test achieves >99% sensitivity while simultaneously analyzing somatic and germline variants in a single run, including structural variants, TMB, MSI, and HRD.
Whole-Genome Interpretation at Scale
Inocras differentiates by focusing on the interpretation layer rather than sequencing hardware. Its CancerVision, MRDVision, and RareVision assays deliver results in two weeks from a CAP/CLIA-certified lab. A collaboration with the Broad Institute analyzed 8,000 TCGA whole cancer genomes, uncovering new driver mutations and pathogenic germline variants in 10% of cases. CEO Jehee Suh noted the shift:
"Sequencing was never the bottleneck — interpretation was."
This positions Inocras against panel-focused players like Foundation Medicine and Caris Life Sciences, which rely on narrower genomic coverage.
Strategic Investors Signal Validation
NDS Corporation and Aimed Bio are both existing commercial partners. NDS partnered in March 2026 to deliver cloud-based genomic analytics, while Aimed Bio signed a July 2026 agreement to integrate whole-genome data into ADC clinical programs. Their dual role as investors and collaborators underscores technology fit. The broader syndicate of Korean financial institutions reflects confidence in Inocras's transition from Asian clinical traction to U.S. market entry.
WGS Market Accelerates
The global whole genome sequencing market is projected to grow from $2.1 billion to $6.1-6.7 billion by 2030 at a 22.2% CAGR, according to Grand View Research. Precision oncology is expected to reach $202-341 billion by 2030. Inocras's oversubscribed round and Broad Institute validation arrive as costs drop and AI interpretation matures, enabling broader clinical adoption of full-genome analysis.
Leadership with Commercial Experience
CEO Jehee Suh previously served as a McKinsey partner and Novartis brand manager. The founding team includes physician-scientists from KAIST with publications in Nature and Cell. The company maintains dual operations in San Diego and Seoul.
U.S. Expansion Underway
With the new capital, Inocras plans to expand clinical presence in the United States, support hospital adoption, and build evidence for whole-genome analysis as standard care. The company aims to leverage its Asian deployment experience across thousands of patient cases for U.S. market entry.